Gamma radiation exposure of accompanying persons due to Lu-177 patients


Kovan B., Demir B., Tuncman D., ÇAPALI V. , Turkmen C.

International Workshop on Theoretical and Experimental Studies in Nuclear Applications and Technology (TESNAT), Osmaniye, Türkiye, 23 - 26 Nisan 2015, cilt.100 identifier identifier

Özet

Neuroendocrine tumours (NET) are cancers usually observed and arisen in the stomach, intestine, pancreas and breathing system. Recently, radionuclide therapy applications with Lu-177 peptide compound are rapidly growing; especially effective clinical results are obtained in the treatment of well-differentiated and metastatic NET. In this treatment, Lu-177-DOTA, a beta emitter radioisotope in the radiopharmaceutical form, is given to the patient by intravenous way. Lu-177 has also gamma rays apart from beta rays. Gamma rays have 175 keV average energy and these gamma rays should be under the control in terms of radiation protection. In this study, we measured the exposure dose from the Lu-177 patient.